Probiotic Lactobacillus plantarum IS-10506, Expression of Glial Fibrillary Acidic Protein and Platelet Endothelial Cell Adhesion Molecule-1 by Astrocytes and Endothelial Integrity: The Importance of Intestinal Microbiota as Blood Brain–Barrier Stabilizer
R. Ranuh, A. F. Athiyyah, A. Darma, W. Riawan, P. Gunawan, I. Surono, S. Sudarmo
{"title":"Probiotic Lactobacillus plantarum IS-10506, Expression of Glial Fibrillary Acidic Protein and Platelet Endothelial Cell Adhesion Molecule-1 by Astrocytes and Endothelial Integrity: The Importance of Intestinal Microbiota as Blood Brain–Barrier Stabilizer","authors":"R. Ranuh, A. F. Athiyyah, A. Darma, W. Riawan, P. Gunawan, I. Surono, S. Sudarmo","doi":"10.37290/ijpp2641-7197.17:21-26","DOIUrl":null,"url":null,"abstract":"Gut microbiota is a complex community that helps maintain the dynamic metabolic ecological balance of the brain through the gut–brain axis and keeps the blood–brain barrier structure intact. However, the knowledge of how the gut microbiota responds to exogenous influences on the blood–brain barrier structure remains limited. This study hypothesizes that probiotic Lactobacillus plantarum IS 10506 supplementations could ameliorate the disruption of the blood–brain barrier structure. To this end, we examined effect of the probiotic L. plantarum IS 10506 on the expression of glial fibrillary acidic protein and platelet endothelial cell adhesion molecule-1 in the control and E. coli serotype O55:B5 lipopolysaccharide treated blood–brain barrier disruption model of Wistar rats. The rats receiving L. plantarum IS 10506 alone or along with E. coli serotype O55:B5 lipopolysaccharide exhibited upregulation of the expression of glial fibrillary acidic protein and platelet endothelial cell adhesion molecule-1. In conclusion, the probiotic L. plantarum IS-10506 stimulates the restoration of blood–brain barrier disruption.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Probiotics and Prebiotics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37290/ijpp2641-7197.17:21-26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
Abstract
Gut microbiota is a complex community that helps maintain the dynamic metabolic ecological balance of the brain through the gut–brain axis and keeps the blood–brain barrier structure intact. However, the knowledge of how the gut microbiota responds to exogenous influences on the blood–brain barrier structure remains limited. This study hypothesizes that probiotic Lactobacillus plantarum IS 10506 supplementations could ameliorate the disruption of the blood–brain barrier structure. To this end, we examined effect of the probiotic L. plantarum IS 10506 on the expression of glial fibrillary acidic protein and platelet endothelial cell adhesion molecule-1 in the control and E. coli serotype O55:B5 lipopolysaccharide treated blood–brain barrier disruption model of Wistar rats. The rats receiving L. plantarum IS 10506 alone or along with E. coli serotype O55:B5 lipopolysaccharide exhibited upregulation of the expression of glial fibrillary acidic protein and platelet endothelial cell adhesion molecule-1. In conclusion, the probiotic L. plantarum IS-10506 stimulates the restoration of blood–brain barrier disruption.
期刊介绍:
The International journal of Probiotics & Prebiotics publishes on online only in an open access format. This is a broad based international, interdisciplinary peer reviewed scientific journal for critical evaluation of research on prebiotics, probiotics and synbiotics. The major goal of this journal is to provide unbiased scientific data to students, researchers, healthcare providers, and the decision makers in the nutraceutical industry to help make informed choices about prebiotics, probiotics and synbiotics. To this end, the journal will publish original research articles and two types of review articles. First, we will publish a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, we will publish a critical evaluation of current human experimental data to help deliver products with medically proven use.